JUST LAUNCHED!

The MBC Alliance is honored to have served as a catalyst and partner in the creation and launch of a new website, MBCBrainMets.org.

As the first one-stop resource hub for breast cancer patients living with brain metastasis or leptomeningeal disease, the new site was curated by fellow patients and supported by funding from nonprofit Alliance member SHARE Cancer Support. By sharing cutting-edge information and resources in a simple format, the site connects people living with brain metastasis to knowledge and support tailored specifically to their needs.

Created by patient advocates to fill an unmet need.

READ MORE!
ButtonTrio-final2

October MAY BE Breast Cancer Awareness Month, but Metastatic Breast Cancer is
Here All Year.
Help us spread the word… year-round!

Each month, our Here All Year campaign explores a new topic around metastatic breast cancer—from myth and stigma busters, to new research and strategies for improving outcomes. Want to help make a difference for people living with MBC, all year long? Dig deeper into the research, explore the available resources and share them on your social and email channels.

OCTOBER 2021 | Revisit Here All Year Highlights & Test Your MBC Knowledge

TAKE THE QUIZ!

SPECIAL NEWS UPDATES

THE MBC COMMUNITY AND COVID-19

Click on the slides below to access the latest information from Alliance members and partners.
(Hover over the image and click on the right/left arrows to control the slideshow.)

Home2.0-3

Let’s accelerate metastatic breast cancer research together.

MBC Connect 2.0 is an interactive, web and mobile-friendly, patient experience registry where you can share information about your MBC disease history, experiences, and quality of life – and now, get potential matches to clinical trials. Join today, or update your app to access the latest features.

MBC Alliance Publishes Fourth Article in our Epidemiology Series

New Study Shows Regional Differences in Improved Survival of Patients with
De Novo Metastatic Breast Cancer Over Time

NEW YORK, Oct. 23, 2019 /PRNewswire/ — A retrospective analysis – reported in the journal Cancer by Judith Malmgren, PhD, and co-authors – studied patients in the Surveillance, Epidemiology, and End Results (SEER) 9 population and an institutional cohort with de novo metastatic breast cancer (MBC), which is a first diagnosis of breast cancer that is stage IV. The SEER 9 population includes cancer patients in nine US regions including Seattle-Puget Sound, and is representative of the US population. The institutional cohort includes patients with breast cancer who are followed over time, who live in the Seattle-Puget Sound registry area, and whose cases are included in SEER Seattle-Puget Sound. Approximately 13,000 new cases of de novo MBC are diagnosed annually in the United States.

READ THE PRESS RELEASE

READ THE ARTICLE

READ THE BLOG POST

Welcome to the Precision Medicine* Revolution

*PRECISION MEDICINE is a form of medicine that uses information about a person’s genes, proteins, and environment to prevent, diagnose, and treat disease. In cancer, precision medicine uses specific information about a person’s tumor to help diagnose, plan treatment, find out how well treatment is working, or make a prognosis. Examples of precision medicine include using targeted therapies to treat specific types of cancer cell, such as HER2-positive breast cancer cells, or using tumor marker testing to help diagnose cancer.
Also called personalized medicine.

LEARN MORE

UPDATE!
Expanded Metastatic Breast Cancer Trial Search

We are excited to present the updated Metastatic Breast Cancer Trial Search, the first-ever clinical trial
search engine designed specifically for people with Metastatic Breast Cancer.

Click on the button below to enter your health information
and find trials that are right for you:

PLUS – Introducing Metastatic Trial Talk

A new companion portal that provides patients with carefully selected
news and features about metastatic breast cancer research.

MBC Alliance Clinical Trials Education Initiative